Table 1 Demographic data for the eighty-three participants that were included in the behavioural analysis.

From: Interaction of schizophrenia and chronic cannabis use on reward anticipation sensitivity

Measure

HC−C (n = 27)

HC + C (n = 22)

SZ-C (n = 21)

SZ + C (n = 13)

p

Age (years)

27.82 (4.63)

27.05 (7.72)

30.29 (8.00)

23.92 (4.75)

0.056a

Sex (% male)

63

77

81

92

0.16b

Education level (years)

15.63 (0.79)

14.64 (1.68)

12.76 (1.86)

13.46 (1.66)

<0.0001a

Clinical data

     

Chlorpromazine equivalent (mg)

  

522 (410)

829 (538)

0.09c

Disorder duration (years)

  

3.50 (4.18)

1.62 (1.93)

0.13c

Number of hospitalizations

  

1.44 (0.94)

1.09 (0.54)

0.32c

Cannabis use

     

Lifetime use (times used)

3.2 (5.4)

3443.8 (4949)

0.8 (1.2)

3488.3 (4896)

0.98c

Duration of use (years)

 

7.78 (5.42)

 

6.67 (4.16)

0.54c

Frequency of use (per week)

 

6.45 (4.16)

 

8.58 (8.44)

0.33c

Age of first use (years)

 

16.91 (2.09)

 

15.46 (2.22)

0.06c

  1. Duration, frequency and age of first use for HC−C and SZ−C were not reported since most of them did not use cannabis. Lifetime use is an estimation based on duration and frequency of use. All measures apart from sex are equivalent to the mean of the respective group. Parentheses indicate standard deviation.
  2. Bold typeface = p < 0.05. p values for all cannabis use variables indicate significance for testing differences between HC + C and SZ + C.
  3. HC−C non-cannabis user healthy controls, HC + C cannabis-user healthy controls, SZ−C non-cannabis user schizophrenia patients, SZ + C cannabis-user schizophrenia patients.
  4. aAnalysis of variance (ANOVA) was used.
  5. bChi-square test was used.
  6. cIndependent samples t-test was used.
Back to article page